Romidepsin and azacitidine in patients with PTCL treated in a real world setting. (A) Mutations identified in patients who had next generation sequencing (blue squares represent mutations in RHOA, IDH2, TET2 and DNMT3A, orange squares are other mutations). (B) Outcomes and duration of response in patients treated with romidepsin and azacitidine in a real-world setting. Green lines: complete remission; yellow lines: partial remission; red lines: progression of disease; black star: allogeneic stem cell transplant; black triangle: autologous stem cell transplant; black arrow: ongoing remission; black St. Andrews cross: death. Frontline treated patients are highlighted on the y axis with blue squares. (C) Overall survival. (D) Progression free survival. (E) Duration of response.